ULTRAVATE (Halobetasol Propionate) Patent Expiration, LOE Window & CMS Spending

ULTRAVATE (Halobetasol Propionate) by Lacer: FDA Orange Book core substance LOE 2033-06-19, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLacer
FDA Application & PathwayN208183 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-06-19
Last Listed Patent or Exclusivity Date2033-06-19
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 31.6% 2-yr change)